Announcements
New Trial Will Evaluate Iron Infusions to Treat Postpartum Anemia Globally
The Foundation for the National Institutes of Health and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the National Institutes of Health (NIH) announce the Prevention of Iron Deficiency Anemia Post-Delivery (PRIORITY) trial.
FNIH Biomarkers Consortium Project Will Characterize a New Imaging Tool Used to Measure Cognitive Decline in Alzheimer’s Disease Patients
The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) has launched a project that signals a paradigm shift in our methods to image the brain.
AMP® BGTC Announces Rare Disease Selection Candidates, Issues Clinical Trial RFP
The Accelerating Medicines Partnership® Bespoke Gene Therapy Consortium (AMP® BGTC) is pleased to announce the completion of the first step of the disease selection process.
FDA Approves Biomarker Qualification Plan for the First Surrogate Endpoint in Anti-Osteoporosis Drug Trials
The Foundation for the National Institutes of Health (FNIH) announces that the Food and Drug Administration (FDA) Biomarkers Qualification Program accepted a qualification plan to use the treatment-related change in bone mineral density (BMD) as a surrogate endpoint for fractures in future trials of new anti-osteoporosis drugs.
FNIH Biomarkers Consortium Launches a Project to Detect the Earliest Changes in Rare Neurodegenerative Diseases
The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has launched a new project that will identify the best blood tests to measure a protein that is instrumental in the early detection of rare neurodegenerative diseases.
FNIH Biomarkers Consortium Project Will Establish New Methods for Detecting Disease in Acute Myeloid Leukemia
The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) has launched a project to validate new methods of detecting and quantifying the small amount of cancer cells remaining in the body following anti-cancer therapy, or measurable residual disease (MRD), in patients with acute myeloid leukemia (AML).
NIMBLE Program Presents First Set of Data on Establishing Non-Invasive Biomarkers to Diagnose Non-Alcoholic Steatohepatitis
North Bethesda, MD, November 15, 2021 – The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, in a groundbreaking program – Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE).
FNIH Biomarkers Consortium Confirms Blood Tests Provide a Key Research Tool for Measuring Amyloid Accumulation in Alzheimer’s Disease
North Bethesda, MD, July 26, 2021—The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium (BC) has evaluated several blood tests that can detect one of the known characteristics of Alzheimer’s disease (AD).
Three Questions with Dr. Gerard Honig on Mucosal Healing Project
June 24, 2021 — Read an interview with Dr. Gerard Honig, project team co-chair and Director of Research Innovation at the Crohn’s & Colitis Foundation.
FNIH Biomarkers Consortium Project Will Transform Clinical Trials for Ulcerative Colitis
April 13, 2021 — The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium has launched a new project that will establish a common and harmonized methodology to define and measure healing in ulcerative colitis (UC).